Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis

Journal of Structural Biology

Volumn 180, Issue 1, 2012, Pages 143-153

  Trivella, Daniela B B ^a,b   dos Reis, Caio V ^a   Lima, Luís Maurício T R ^c   Foguel, Débora ^c   Polikarpov, Igor ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Amyloidosis; Crystal structure; Flavonoid; Isothermal titration calorimetry; TTR amyloid inhibitor; TTR V30M mutant; Wild type TTR

Indexed keywords

APIGENIN; BAICALEIN; FISETIN; FLAVONOID; HYDROXYL GROUP; KAEMPFEROL; LUTEOLIN; MUTANT PROTEIN; NARINGENIN; PREALBUMIN; QUERCETIN;

ARTICLE; BINDING AFFINITY; CHEMICAL BINDING; CHEMICAL INTERACTION; COMPLEX FORMATION; CRYSTAL STRUCTURE; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; THERMODYNAMICS; WILD TYPE; X RAY DIFFRACTION;

AMINO ACID MOTIFS; BINDING SITES; CALORIMETRY; CRYSTALLOGRAPHY, X-RAY; FLAVONOIDS; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; PREALBUMIN; PROTEIN BINDING; PROTEIN MULTIMERIZATION; THERMODYNAMICS;

EID: 84866986722     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2012.07.008     Document Type: Article

References (40)

1. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., et al. PHENIX: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2010, 66:213-221.
2. Adamski-Werner S.L., Palaninathan S.K., Sacchettini J.C., Kelly J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem. 2004, 47:355-374.
3. Andrea T.A., Cavalieri R.R., Goldfine I.D., Jorgensen E.C. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980, 19:55-63.
4. Andricopulo A.D., Guido R.V.C., Trivella D.B.B., Polikarpov I., Leitão A., et al. Recent trends in structure-based drug design and energetics. Burger's Medicinal Chemistry, Drug Discovery 2010, 685-724. John Wiley & Sons, Inc., New York. D.J. Abraham (Ed.).
5. Bartalena L., Robbins J. Thyroid hormone transport proteins. Clin. Lab. Med. 1993, 13:583-598.
6. CCP4, 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D: Biol. Crystallogr. 50, 760-763.
7. Cheng S.Y., Pages R.A., Saroff H.A., Edelhoch H., Robbins J. Analysis of thyroid hormone binding to human serum prealbumin by 8-anilinonaphthalene-1-sulfonate fluorescence. Biochemistry 1977, 16:3707-3713.
8. Connelly S., Choi S., Johnson S.M., Kelly J.W., Wilson I.A. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol. 2010, 20:54-62.
9. Connors L.H., Richardson A.M., Theberge R., Costello C.E. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 2000, 7:54-69.
10. Dundas J., Ouyang Z., Tseng J., Binkowski A., Turpaz Y., et al. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006, 34:W116-W118.
11. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2004, 60:2126-2132.
12. Green N.S., Foss T.R., Kelly J.W. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Natl. Acad. Sci. USA 2005, 102:14545-14550.
13. Guimaraes B.G., Sanfelici L., Neuenschwander R.T., Rodrigues F., Grizolli W.C., et al. The MX2 macromolecular crystallography beamline: a wiggler X-ray source at the LNLS. J. Synchrotron Radiat. 2009, 16:69-75.
14. Hammarstrom P., Wiseman R.L., Powers E.T., Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299:713-716.
15. Johnson S.M., Connelly S., Wilson I.A., Kelly J.W. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J. Med. Chem. 2008, 51:6348-6358.
16. Johnson S.M., Connelly S., Wilson I.A., Kelly J.W. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J. Med. Chem. 2008, 51:260-270.
17. Johnson S.M., Connelly S., Wilson I.A., Kelly J.W. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J. Med. Chem. 2009, 52:1115-1125.
18. Johnson S.M., Wiseman R.L., Sekijima Y., Green N.S., Adamski-Werner S.L., et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Accounts Chem. Res. 2005, 38:911-921.
19. Johnson S.M., Petrassi H.M., Palaninathan S.K., Mohamedmohaideen N.N., Purkey H.E., et al. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J. Med. Chem. 2005, 48:1576-1587.
20. Julius R.L., Hawthorne M.F. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition. Drug News Perspect. 2008, 21:258-266.
21. Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W., et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7:312-321.
22. Lai Z., Colon W., Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996, 35:6470-6482.
23. Leslie A.G. Integration of macromolecular diffraction data. Acta Crystallogr. Sect. D: Biol. Crystallogr. 1999, 55:1696-1702.
24. Leslie A.G. The integration of macromolecular diffraction data. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2006, 62:48-57.
25. Lima L.M., Silva Vde A., Palmieri Lde C., Oliveira M.C., Foguel D., et al. Identification of a novel ligand binding motif in the transthyretin channel. Bioorg. Med. Chem. 2010, 18:100-110.
26. Morais-de-Sa E., Pereira P.J., Saraiva M.J., Damas A.M. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J. Biol. Chem. 2004, 279:53483-53490.
27. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D: Biol. Crystallogr. 1997, 53:240-255.
28. Neumann P., Cody V., Wojtczak A. Structural basis of negative cooperativity in transthyretin. Acta Biochim. Pol. 2001, 48:867-875.
29. Oza V.B., Smith C., Raman P., Koepf E.K., Lashuel H.A., et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 2002, 45:321-332.
30. Petrassi H.M., Johnson S.M., Purkey H.E., Chiang K.P., Walkup T., et al. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J. Am. Chem. Soc. 2005, 127:6662-6671.
31. Polikarpov I., Perles L.A., de Oliveira R.T., Oliva G., Castellano E.E., et al. Set-up and experimental parameters of the protein crystallography beamline at the Brazilian National Synchrotron Laboratory. J. Synchrotron Radiat. 1998, 5:72-76.
32. Quintas A., Saraiva M.J., Brito R.M. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J. Biol. Chem. 1999, 274:32943-32949.
33. SPARC, 2010. SPARC - Automatic Reasoning in Chemistry. http://www.archemcalc.com/sparc.php.
34. Trivella D.B., Sairre M.I., Foguel D., Lima L.M., Polikarpov I. The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition. J. Struct. Biol. 2011, 173:323-332.
35. Trivella D.B., Bleicher L., Palmieri Lde C., Wiggers H.J., Montanari C.A., et al. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. J. Struct. Biol. 2010, 170:522-531.
36. Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8:127-134.
37. Westermark P., Engstrom U., Johnson K.H., Westermark G.T., Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 1990, 87:5036-5040.
38. Wojtczak A., Luft J., Cody V. Mechanism of molecular recognition. Structural aspects of 3,3'-diiodo-l-thyronine binding to human serum transthyretin. J. Biol. Chem. 1992, 267:353-357.
39. Wojtczak A., Cody V., Luft J.R., Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0A resolution and 3',5'-dinitro-N-acetyl-l-thyronine at 2.2A resolution. Acta Crystallogr. Sect. D: Biol. Crystallogr. 1996, 52:758-765.
40. Zanotti G., D'Acunto M.R., Malpeli G., Folli C., Berni R. Crystal structure of the transthyretin-retinoic-acid complex. Eur. J. Biochem. 1995, 234:563-569.